Illumina, Inc. - Common Stock (ILMN)
Healthcare › Laboratory Analytical Instruments
Price History
Feb 9, 2026 — May 9, 2026Investment Snapshot
- Trading 200% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 31.9% with 20.0% net margin
Illumina, Inc. - Common Stock (ILMN) is a Healthcare company operating in Laboratory Analytical Instruments, listed on the NASDAQ , with a market capitalisation of $21.5 billion . Key value metrics: P/E ratio 25.2, P/B ratio 8.02, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Illumina, Inc. - Common Stock — Fundamental Analysis Summary
Illumina, Inc. - Common Stock (ILMN) is currently trading 200% above its Graham Number of $47.37, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 25.2x.
On financial health, ILMN shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 31.9% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for ILMN is 72/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ILMN reports a high gross margin of 66.2% (sector average: 40.1%) and a solid operating margin of 19.0%.
ILMN shows revenue declining at 1% year-over-year, with earnings growing at 170%.